WO2005054239A1 - Derives de 2-aminopyrimidine - Google Patents

Derives de 2-aminopyrimidine Download PDF

Info

Publication number
WO2005054239A1
WO2005054239A1 PCT/EP2004/013322 EP2004013322W WO2005054239A1 WO 2005054239 A1 WO2005054239 A1 WO 2005054239A1 EP 2004013322 W EP2004013322 W EP 2004013322W WO 2005054239 A1 WO2005054239 A1 WO 2005054239A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyrimidin
amine
amino
pyridin
pyrrolo
Prior art date
Application number
PCT/EP2004/013322
Other languages
English (en)
Inventor
Hiroki Sato
Kazuho Tanaka
Makoto Shimazaki
Klaus Urbahns
Katsuya Sakai
Florian Gantner
Kevin Bacon
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of WO2005054239A1 publication Critical patent/WO2005054239A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present invention relates to novel 2-aminopyrimidine derivatives, processes for preparing them and pharmaceutical preparations containing them.
  • the 2-aminopyrimidine derivatives of the present invention exhibit enhanced potency for histamine H4 receptor antagonism and can be used for the prophylaxis and treatment of diseases associated with histamine H4 receptor activity!
  • the 2-aminopyrimidine derivatives of the present invention are useful for treatment and prophylaxis of diseases as follows: asthma, rhinitis, allergic diseases, chronic obstructed pulmonary disease (COPD), atherosclerosis, rheumatoid arthritis, thromboembolic diseases or disorders and urological diseases or disorders.
  • diseases as follows: asthma, rhinitis, allergic diseases, chronic obstructed pulmonary disease (COPD), atherosclerosis, rheumatoid arthritis, thromboembolic diseases or disorders and urological diseases or disorders.
  • Histamine exerts its numerous physiological and pathophysiological functions by acting on its receptor entities which belong to the heptahelical G-protein coupled receptor family.
  • Hough LB Mol Pharmacol, 59:415-419, 2001.
  • the specific functions of HI, H2 and H3 subtypes are well characterized (reviewed in the following references: Bakker RA et al., Clin Allergy Immunol, 17:27-64, 2002; Repka-Ramirez MS and Baraniuk IN, Clin Allergy Immunol, 17:1-25, 2002; Winbery SL and Lieberman PL, Clin Allergy Immunol, 17:287-317, 2002; Barocelli E and Ballabeni V, Pharmacol Res, 47:299-304, 2003.) and antagonists to each subtype are identified and some drugs have been clinically used.
  • the fourth member, H 4 has recently been cloned and characterized by various groups (Oda T et al., J. Biol. Chem. 275(47):36781-36786, 2000; Nakamura T et al, Biochem Biophys Res Commun 279:615-620, 2000; Zhu et al., Mol. Pharmacol. 59(3):434-441, 2001; Liu C et al., Mol. Pharmacol. 59:420-426, 2001; Morse et al., J. Pharmacol. Exp. Ther. 296(3): 1058-1066, 2001; Nguyen et al., Mol. Pharmacol.
  • H4 human eosinophils
  • IL-16 release from human CD8 + lymphocytes
  • H4 calcium mobilization and chemotaxis of murine mast cells
  • antagonists of histamine H4 receptor can be used for prophylaxis and treatment of immunological or inflammatory disorders/diseases, including asthma, rhinitis, allergic diseases, chronic obstructed pulmonary disease (COPD), atherosclerosis and rheumatoid arthritis.
  • immunological or inflammatory disorders/diseases including asthma, rhinitis, allergic diseases, chronic obstructed pulmonary disease (COPD), atherosclerosis and rheumatoid arthritis.
  • WO03/035639 discloses pyrimidine derivatives represented by the general formula:
  • Raj and Ra 2 independently represent hydrogen, optionally substituted C )-6 alkyl etc;
  • Ra 3 is hydrogen, halogeno, optionally substituted C 6 . ⁇ 4 aromatic hydrocarbon ring group, optionally substituted 5 to 14 membered aromatic heterocyclic group etc;
  • Ra 4 is hydrogen, C 6 . aromatic hydrocarbon ring group, optionally substituted 5 to 14 membered aromatic heterocyclic group or optionally substituted 5 to 14 membered nonaromatic heterocyclic group having at least one unsaturatedbond;
  • Ra 5 is hydrogen, C 6- ⁇ 4 aromatic hydrocarbon ring group or optionally substituted 5 to 14 membered aromatic heterocyclic group;
  • WO01/047921 discloses pyrimidine derivatives represented by the general formula:
  • Rbj is hydrogen, alkyl, alkoxyalkyl, arylalkyl, heteroaryl, heteroarylalkyl etc;
  • Rb 2 is halogen, alkyl, OH, (un)substituted heteroaryl, (un)substituted heterocyclyl, etc;
  • Rb 3 is bond
  • Rb 4 is hydrogen, halogen, alkyl, heterocyclyl, alkylamino, etc;
  • Y is hydrogen, alkyl, or Y and Rb ! together with N to form (un)substituted heterocyclyl or heteroaryl;
  • Rcj and Rc 4 independently represent hydrogen, amino, (un)substituted phenyl etc;
  • Rc 2 is hydrogen, alkyl, alkenyl, etc., or alkylene or alkenylene to form ring together with Q-A-N, etc;
  • Rc 3 is H, alkyl or alkenyl
  • A is direct bond, alkylene or oxy-alkylene
  • Q is pyridyl, furyl, thienyl or (un)substituted phenyl. ermediate for a cardiovascular agent.
  • 62233 discloses pyrimidine derivatives represented by the general formula:
  • Ad is bond, -N(R)-, etc;
  • Rdj is hydrogen, -(CH 2 ) n -phenyl, -(CH 2 ) n -piperazin-4-yl optionally substituted by lower alkyl, phenyl, -(CH 2 ) n -pi ⁇ eridinyl optionally substituted by lower alkyl, -(CH 2 ) n - NH-phenyl etc;
  • n is an integer of 0-4;
  • Rd 2 is hydrogen, halogen, cyano, alkyl, etc;
  • Rd 3 is lower alkyl, phenyl optionally substituted by alkyl, alkoxy or halogen, heterocycles (eg. thienyl, furyl) etc;
  • Rd 4 and Rd 5 independently represent hydrogen, optionally substituted phenyl, etc. enosine receptor modulators. 30 discloses pyrimidine derivatives represented by the general formula:
  • Re 2 and Re 2 are independently OH or N Re 9 Re 10 ;
  • Re 9 and Re 10 independently represent hydrogen, alkyl etc, or together with nitrogen to form a ring, which is optionally substituted by alkyl, aryl or arylalkyl;
  • Re 3 is hydrogen, haloalkyl, halogen, alkyl, etc;
  • Re 4 , Re 5 , Re 6 , Re 7 and Re 8 independently represent hydrogen, halogen, amino sulphon- amido, or alkylsulphonylamino, with the proviso that at least one of R e 4 -R e 8 is not hydrogen.
  • WO02/072548 discloses indole derivatives as histamine H4 receptor antagonist.
  • This invention is to provide novel 2-aminopyrimidine derivatives of the formula (I) their tauto- meric and stereoisomeric forms, and salts thereof.
  • R 1 represents wherein m represents an integer of 1, 2 or 3; n represents an integer of 0 or 1; R 11 represents hydrogen or C 1-6 alkyl optionally substituted by halogen, cyano, hydroxy, carboxy, amino, N-(C ⁇ -6 a_kyl)amino, N,N-di(C ⁇ -6 alkyl)amino, C 1-6 alkylthio, C ⁇ -6 alkoxy, or C 3-8 cycloalkyl;
  • R 12 and R 13 independently represent hydrogen or C 1-6 alkyl optionally substituted by halogen, cyano, hydroxy, carboxy, amino, N-(C ⁇ . 6 alkyl)amino, N,N-di(C ⁇ _ 6 alkyl)amino, C ⁇ -6 alkylthio, C ⁇ -6 alkoxy, or C 3-8 cycloalkyl;
  • R 2 represents hydrogen, halogen or C ⁇ . 6 alkyl
  • R 3 represents aryl or heteroaryl, wherein said aryl and heteroaryl are optionally having one or more substituents selected from the group consisting of halogen, carboxy, hydroxy, cyano, nitro, C 3 8- cycloalkyl, phenyl, C ⁇ -6 alkanoyl, amino, N-(C ⁇ . 6 alkyl)amino, N-(C 1-6 alkanoyl)- amino, N-(C ⁇ -6 alkylsulfonyl)amino, N-(phenylsulfonyl)amino, N-(C ⁇ -6 alkoxy- cabonyl)amino, N-(aryl)amino, N-(aryl C ⁇ .
  • C ⁇ -fi alkyl optionally substituted by cyano, hydroxy, carboxy, amino, N-(C ]-6 alkyl)- amino, N,N-di(C 1 . 6 alkyl)amino, C ⁇ -6 alkylthio, C 1-6 alkoxy, or mono-, di-, or tri- halogen, and C 1-6 alkoxy optionally substituted by C 3-8 cycloalkyl, or mono-, di-, or tri- halogen.
  • the present invention provides 2-aminopyrimidine derivatives of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof:
  • R 1 represents
  • R 11 represents hydrogen or C ⁇ -6 alkyl
  • R 12 and R 13 independently represent hydrogen or C ⁇ -6 alkyl.
  • the present invention provides 2-aminopyrimidine derivatives of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof:
  • R 1 represents
  • R 11 represents hydrogen or C ⁇ -6 alkyl
  • R 12 and R 13 independently represent hydrogen or C ⁇ -6 alkyl
  • R 2 represents hydrogen, fluoro, chloro, methyl, ethyl or propyl
  • R 3 represents phenyl, naphthyl or thienyl, wherein said phenyl or naphthyl are optionally having one or two substituents selected from the group consisting of halogen, carboxy, hydroxy, cyano, nitro, C 3- scycloalkyl, phenyl, C ⁇ -6 alkanoyl, amino, N-(C ⁇ -6 alkyl)amino, N,N-di(C ⁇ -6 alkyl)amino, N- (C ⁇ -6 alkylsulfonyl)amino, N-(phenylsulfonyl)amino, N-(C ⁇ . 6 alkanoyl)amino, N-(C ⁇ .
  • C 1-6 alkyl optionally substituted by cyano, hydroxy, carboxy, amino, N-(C ⁇ -6 alkyl)- amino, N,N-di(C ⁇ -6 alkyl)amino, C ⁇ - ⁇ alkylthio, C ⁇ -6 alkoxy, or mono-, di-, or tri- halogen, and
  • C ⁇ -6 alkoxy optionally substituted by C 3-8 cycloalkyl, or mono-, di-, or tri- halogen.
  • the present invention provides 2-aminopyrimidine derivatives of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof:
  • R 1 represents
  • R 11 represents hydrogen, methyl or ethyl
  • R 12 and R 13 independently represent hydrogen, methyl or ethyl
  • R 2 represents hydrogen, fluoro, chloro, methyl, or ethyl
  • R 3 represents phenyl optionally having one or two substituents selected from the group consisting of halogen, hydroxy, cyano, nitro, phenyl, amino, N,N- di(C ⁇ -6 alkyl)amino, C ⁇ -6 alkylcarbonyl,
  • C ⁇ -6 alkyl optionally substituted by hydroxy, or mono-, di-, or tri- halogen
  • C 1-6 alkoxy optionally substituted by C 3-8 cycloalkyl, or mono-, di-, or tri- halogen.
  • the present invention provides 2-aminopyrimidine derivatives of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof:
  • R 1 represents
  • R n represents hydrogen, methyl or ethyl
  • R 12 and R 13 independently represent hydrogen, methyl or ethyl
  • R 2 represents hydrogen or fluoro; and .
  • R 3 represents phenyl optionally having one or two substituent selected from the group consisting of fluoro, chloro, hydroxy, cyano, nitro, amino, N,N-(dimethyl)amino, methyl, ethyl, propyl, trifluoromethyl, methoxy, ethoxy, trifluoromethoxy, cyclopropylmethoxy, acetyl, or phenyl.
  • the present invention provides 2-aminopyrimidine derivatives of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof:
  • said 2-aminopyrimidine derivative of the formula (I) is selected from the group consisting of: 4-[(4aR,7aR)-octahydro-6H-py ⁇ olo[3,4-b] ⁇ yridin-6-yl]-6-phenylpyrimidin-2-amine trihydrochloride;
  • this invention is to provide a use of the 2-aminopyrimidine derivatives of the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof in the preparation of a medicament.
  • said medicament is suitable for treating or preventing a disorder or disease associated with histamine H4 receptor activity.
  • the 2-aminopyrimidine derivatives of the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof surprisingly show excellent histamine H4 receptor antagonistic activity. They are, therefore, suitable for the production of medicament or medical composition, which may be useful to treat histamine H4 receptor related diseases.
  • compounds of the formula (I) are effective for the treatment or prevention of an inflammatory disorder or disease such as asthma, rhinitis, allergic diseases or chronic obstructed pulmonary disease (COPD).
  • an inflammatory disorder or disease such as asthma, rhinitis, allergic diseases or chronic obstructed pulmonary disease (COPD).
  • COPD chronic obstructed pulmonary disease
  • compounds of the formula (I) are effective for the treatment or prevention of an immunological disorder or disease such as rheumatoid arthritis or atherosclerosis.
  • compounds of the formula (I) are effective for the treatment or prevention of thromboembolic disorders, in particular myocardial infarct, angina pectoris (including unstable angina), reocclusions and restenoses after angioplasty or aorto-coronary bypass, stroke, transitory ischaemic attacks, peripheral arterial occlusive diseases, pulmonary embolisms or deep venous thromboses.
  • compounds of the formula (I) are effective for the treatment or prevention of pulmonary and malignant hypertension, cardiac insufficiency, heart and kidney failure, of ischaemic disorders such as angina pectoris, myocardial infarction and stroke and of cardial arrhythmia and renal dysfunction.
  • compounds of the formula (I) are effective for the treatment or prevention of urological diseases or disorders, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor oeractivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms.
  • the present invention provides a medicament, which includes one of the compounds described above and optionally pharmaceutically acceptable excipients.
  • Alkyl per se and "alk” and “alkyl” in alkoxy, alkanoyl, alkylamino, alkylaminocarbonyl, alkyl- aminosulphonyl, alkylsulphonylamino, alkoxycarbonyl, alkoxycarbonylamino and alkanoylamino represent a linear or branched alkyl radical having generally 1 to 6, preferably 1 to 4 and particularly preferably 1 to 3 carbon atoms, representing illustratively and preferably methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-pentyl and n-hexyl.
  • Alkoxy illustratively and preferably represents methoxy, ethoxy, n-propoxy, isopropoxy, tert- butoxy, n-pentoxy and n-hexoxy.
  • Alkanoyl illustratively and preferably represents acetyl and propanoyl.
  • Alkylamino represents an alkylamino radical having one or two (independently selected) alkyl substituents, illustratively and preferably representing methylamino, ethylamino, n-propylamino, isopropylamino, tert-butylamino, n-pentylamino, n-hexyl-amino, N,N-dimethylamino, N,N- diethylamino, N-ethyl-N-methylamino, N-methyl-N-n-propylamino, N-isopropyl-N-n-propylamino, N-t-butyl-N-methylamino, N-ethyl-N-n-pentylamino and N-n-hexyl-N-methylamino.
  • Alkylaminocarbonyl or alkylcarbamoyl represents an alkylaminocarbonyl radical having one or two (independently selected) alkyl substituents, illustratively and preferably representing methylaminocarbonyl, ethylaminocarbonyl, n-propylaminocarbonyl, isopropylamino-carbonyl, tert-butylaminocarbonyl, n-pentylaminocarbonyl, n-hexylaminocarbonyl, N,N-dimethyl- aminocarbonyl, N,N-diethylaminocarbonyl, N-ethyl-N-methylaminocarbonyl, N-methyl-N-n- propylammocarbonyl, N-isopropyl-N-n-propylaminocarbonyl, N-t-butyl-N-methylaminocarbonyl, N-ethyl-N-pentylamino
  • Alkylaminosulphonyl represents an alkylaminosulphonyl radical having one or two (independently selected) alkyl substituents, illustratively and preferably representing methylaminosulphonyl, ethylaminosulphonyl, n-propylaminosulphonyl, isopropylaminosulphonyl, tert-butylamino- sulphonyl, n-pentylaminosulphonyl, n-hexyl-aminosulphonyl, N,N-dimethylaminosulphonyl, N,N- diethylaminosulphonyl, N-ethyl-N-methylamino-sulphonyl, N-methyl-N-n-propylaminosulphonyl, N-isopropyl-N-n-propylaminosulphonyl, N-t-butyl-N-methylaminosulphonyl, N-ethyl-N
  • Alkylsulphonylamino illustratively and preferably represents methylsulphonylamino, ethyl- sulphonylamino, n-propylsulphonylamino, isopropylsulphonylamino, tert-butyl-sulphonylamino, n- pentylsulphonylamino and n-hexylsulphonylamino.
  • Alkoxycarbonyl illustratively and preferably represents methoxycarbonyl, ethoxycarbonyl, n- propoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl, n-pentoxycarbonyl and n-hexoxy- carbonyl.
  • Alkoxycarbonylamino illustratively and preferably represents methoxycarbonylamino, ethoxycarbonylamino, n-propoxycarbonylarnino, isopropoxycarbonylamino, tert-butoxy- carbonylamino, n-pentoxycarbonylamino and n-hexoxycarbonylamino.
  • Alkanoylamino illustratively and preferably represents acetylamino and ethylcarbonylamino.
  • Cycloalkyl per se and in cycloalkylamino and in cycloalkylcarbonyl represents a cycloalkyl group having generally 3 to 8 and preferably 5 to 7 carbon atoms, illustratively and preferably representing cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • Cycloalkylamino represents a cycloalkylamino radical having one or two (independently selected) cycloalkyl substituents, illustratively and preferably representing cyclopropylamino, cyclobutylamino, cyclopentylamino, cyclohexylamino and cycloheptylamino.
  • Cycloalkylcarbonyl illustratively and preferably represents cyclopropylcarbonyl, cyclobutyl- carbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl and cycloheptylcarbonyl.
  • Aryl per se and in arylamino and in arylcarbonyl represents a mono- to tricyclic aromatic carbocyclic radical having generally 6 to 14 carbon atoms, illustratively and preferably representing phenyl, naphthyl and phenanthrenyl.
  • Arylamino represents an arylamino radical having one or two (independently selected) aryl substituents, illustratively and preferably representing phenylamino, diphenylamino and naphthylamino.
  • Arylcarbonyl illustratively and preferably represents phenylcarbonyl and naphthylcarbonyl.
  • Heteroaryl per se and in heteroarylamino and heteroarylcarbonyl represents an aromatic mono- or bicyclic radical having generally 5 to 10 and preferably 5 or 6 ring atoms and up to 5 and preferably up to 4 hetero atoms selected from the group consisting of S, O and N, illustratively and preferably representing thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, pyridyl, pyrimidyl, pyridazinyl, indolyl, indazolyl, benzofuranyl, benzothiophenyl, quinolinyl, isoquinolinyl.
  • Heteroarylamino represents an heteroarylamino radical having one or two (independently selected) heteroaryl substituents, illustratively and preferably representing thienylamino, furylamino, pyrrolylamino, thiazolylamino, oxazolylamino, imidazolyl-amino, pyridylamino, pyrimidylamino, pyridazinylamino, indolylamino, indazolylamino, benzofuranylamino, benzothiophenylamino, quinolinyl-amino, isoquinolinylamino.
  • Heteroarylcarbonyl illustratively and preferably represents thienylcarbonyl, furylcarbonyl, pyr- rolylcarbonyl, thiazolylcarbonyl, oxazolylcarbonyl, imidazolyl-carbonyl, pyridylcarbonyl, pyrimidylcarbonyl, pyridazinylcarbonyl, indolylcarbonyl, indazolylcarbonyl, benzofuranyl- carbonyl, benzothiophenylcarbonyl, quinolinyl-carbonyl, isoquinolinylcarbonyl.
  • Heterocyclyl per se and in heterocyclylcarbonyl represents a mono- or polycyclic, preferably mono- or bicyclic, nonaromatic heterocyclic radical having generally 4 to 10 and preferably 5 to 8 ring atoms and up to 3 and preferably up to 2 hetero atoms and/or hetero groups selected from the group consisting of N, O, S, SO and SO 2 .
  • the heterocyclyl radicals can be saturated or partially unsaturated.
  • Heterocyclylcarbonyl illustratively and preferably represents tetrahydrofuran-2-carbonyl, pyrrolidine- 2-carbonyl, pyrrolidine-3-carbonyl, pyrrolinecarbonyl,. piperidinecarbonyl, morpholinecarbonyl, perhydroazepinecarbonyl.
  • Halogen represents fluorine, chlorine, bromine and iodine.
  • the compound of the formula (I) of the present invention can be, but not limited to be, prepared by combining various known methods.
  • one or more of the substituents, such as amino group, carboxyl group, and hydroxyl group of the compounds used as starting materials or intermediates are advantageously protected by a protecting group known to those skilled in the art. Examples of the protecting groups are described in "Protective Groups in Organic Synthesis (3rd Edition)" by Greene and Wuts, John Wiley and Sons, New York 1999.
  • the compound of the formula (I) of the present invention can be, but not limited to be, prepared by the Method [A], [B] and [C] below.
  • Step A-l compound of formula (IV) (wherein R 2 and R 3 are the same as defined above) can be prepared by the reaction of compound of formula (H) (wherein R 2 and R 3 are the same as defined above) with compound of formula (DI) or any salt form of (DI).
  • the reaction can be advantageously carried out in the presence of a base including, for instance, sodium hydride, potassium hydride, sodium methoxide, sodium ethoxide, sodium hydroxide or potassium hydroxide, and the like.
  • a base including, for instance, sodium hydride, potassium hydride, sodium methoxide, sodium ethoxide, sodium hydroxide or potassium hydroxide, and the like.
  • the reaction may be carried out in a solvent including, for instance, alcohols such as methanol, ethanol, 1-propanol, isopropanol and tert-butanol and others.
  • alcohols such as methanol, ethanol, 1-propanol, isopropanol and tert-butanol and others.
  • two or more of the solvents selected from the listed above can be mixed and used.
  • the reaction temperature can be optionally set depending on the compounds to be reacted.
  • the reaction temperature is usually, but not limited to, about 20°C to 120°C.
  • the reaction may be conducted for, usually, 30 minutes to 48 hours and preferably 1 to 24 hours.
  • Step A-2 compound of the formula (V) (wherein R 2 and R 3 are the same as defined above and Xi represents a leaving group including, for instance, halogen atom such as chlorine or bromine atom, or triflate) can be prepared by the reaction of compound of formula (IV) (wherein R 2 and R 3 are the same as defined above) with an appropriate halogenating reagent including, for instance, POCl 3 , POBr 3 , PC1 5 , and the like.
  • an appropriate halogenating reagent including, for instance, POCl 3 , POBr 3 , PC1 5 , and the like.
  • the reaction may be carried out without solvent or in a solvent including, for instance, halogenated hydrocarbons such as dichloromethane, chloroform and 1,2-dichloroethane; aromatic hydrocarbons such as benzene, and others.
  • halogenated hydrocarbons such as dichloromethane, chloroform and 1,2-dichloroethane
  • aromatic hydrocarbons such as benzene, and others.
  • the reaction can be advantageously conducted in the presence of a base, including, for instance, such as pyridine, triethylamine and N,N-diisopropylethylamine, dimethylaniline, diethylaniline, and others.
  • a base including, for instance, such as pyridine, triethylamine and N,N-diisopropylethylamine, dimethylaniline, diethylaniline, and others.
  • the reaction temperature can be optionally set depending on the compounds to be reacted.
  • the reaction temperature is usually, but not limited to, about 0°C to 200°C and preferably about 20°C to 150°C.
  • the reaction may be conducted for, usually, 10 minutes to 48 hours and preferably 30minutes to 24 hours.
  • Step A-3 compound of formula (I) (wherein R 1 , R 2 and R 3 are the same as defined above) can be prepared by the reaction of the compound of formula (V) (wherein R 2 , R 3 and i are the same as defined above) with compound of formula (VI) (wherein R 1 is the same as defined above).
  • the reaction may be carried out without solvent or in a solvent including, for instance, halogenated hydrocarbons such as dichloromethane, chloroform and 1,2-dichloroethane; alcohols such as methanol, ethanol, 1-propanol, isopropanol and tert-butanol; ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene and xylene; nitriles such as acetonitrile; amides such as N, N- dimethylformamide (DMF), N, N-dimethylacetamide (DMAC) and N-methylpyrrolidone (NMP); urea such as l,3-dimethyl-2-irnidazolidinone (DMI); sulfoxides such as dimethylsulfoxide (DMSO);
  • the reaction temperature can be optionally set depending on the compounds to be reacted.
  • the reaction temperature is usually, but not limited to, about 0°C to 200°C and preferably about 20°C to 150"C.
  • the reaction may be conducted for, usually, 10 minutes to 48 hours and preferably 30 minutes to 24 hours.
  • the reaction can be advantageously carried out in the presence of a base including, for instance, organic amines such as pyridine, triethylamine, N,N-diis ⁇ propylethylamine, dimethylaniline, diethylaniline, and others.
  • a base including, for instance, organic amines such as pyridine, triethylamine, N,N-diis ⁇ propylethylamine, dimethylaniline, diethylaniline, and others.
  • the compound of formula (II), (DI) including any salt form of (DI) or (VI) can be prepared by the use of known techniques or are commercially available.
  • the compound of formula (T) (wherein R 1 and R 3 are the same as defined above and R 2 is hydrogen) can be prepared, for example, in two steps.
  • Step B-la compound of formula (VIH) (wherein R 1 , R 2' and X ! are the same as defined above) can be prepared by the reaction of compound of formula (VH) (wherein R 2 and Xj is the same as defined above) with compound of formula (VI) (wherein R 1 is the same as defined above) in a similar manner described in Step A-3 for the preparation of compound of the formula (I).
  • Step B-2a compound of formula (F) (wherein R 1 and R 3 are the same as defined above and R 2' is hydrogen) can be prepared by the reaction of compound of formula (VIII) (wherein R 1 , R 2' and Xi are the same as defined above) with compound of formula (IX) (wherein R 3 is the same as defined above and Li represents metal group including, for instance, organoborane group such as boronic acid and dimethoxy boryl; organostannyl group such as tributyl stannyl, and the like).
  • the reaction can be advantageously carried out in the presence of a palladium catalyst such as tetrakis(triphenylphosphine)palladium.
  • a palladium catalyst such as tetrakis(triphenylphosphine)palladium.
  • the reaction can be advantageously carried out in the presence of a base including, for instance, cesium carbonate, sodium carbonate and potassium carbonate, and the like.
  • the reaction may be carried out in a solvent including, for instance, ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene and xylene; amides such as N, N-dimethylformamide (DMF), N, N-dimethylacetamide and N-methylpyrrolidone; sulfoxides such as dimethylsulfoxide (DMSO); alcohols such as methanol, ethanol, 1-propanol, isopropanol and tert-butanol and others.
  • ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2-dimethoxyethane
  • aromatic hydrocarbons such as benzene, toluene and xylene
  • amides
  • the reaction temperature can be optionally set depending on the compounds to be reacted.
  • the reaction temperature is usually, but not limited to, about 20°C to 120°C.
  • the reaction may be conducted for, usually, 30 minutes to 48 hours and preferably 1 to 24 hours.
  • Step B-lb compound of formula (V) (wherein R 2' , R 3 and Xi are the same as defined above) can be prepared by the reaction of compound of formula (VH) (wherein R 2 and Xi are the same as defined above) with compound of formula (DC) (wherein L_ and R 3 are the same as defined above) in a similar manner described in Step B-2a for the preparation of compound of the formula (F).
  • Step B-2b compound of formula (?) (wherein R 1 , R 2 arid R 3 are the same as defined above) can be prepared by the reaction of compound of formula (V) (wherein R 2 , R 3 and Xi are the same as defined above) with compound of formula (VI) (wherein R 1 is the same as defined above) in a similar manner described in Step B-la for the preparation of compound of the formula (VIII).
  • the compound of formula (DC) can be prepared by the use of known techniques or are commercially available.
  • compound of formula (XI) (wherein R 2 and R 3 are the same as defined above) can be prepared by the reaction of the compound of formula (X) (wherein R 3 is the same as defined above) with methyl iodide and carbon disulfide in the presence of a base including, for instance, sodium hydride, potassium hydride, sodium methoxdde or sodium ethoxide, sodium hydroxide or potassium hydroxide.
  • a base including, for instance, sodium hydride, potassium hydride, sodium methoxdde or sodium ethoxide, sodium hydroxide or potassium hydroxide.
  • the reaction can be carried out in a solvent including, for instance, halogenated hydrocarbons such as dichloromethane, chloroform and 1,2-dichloroethane; ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene and xylene; dimethylformamide (DMF), dimethylacetamide (DMAC), 1,3- dimethyl-3,4,5,6-tetrahydro-2(lH)-pyrimidinone (DMPU), l,3-dimethyl-2-imidazolidinone (DMI), N-methylpyrrolidinone (NMP), sulfoxides such as dimethylsulfoxide (DMSO), and others.
  • halogenated hydrocarbons such as dichloromethane, chloroform and 1,2-dichloroethane
  • ethers such as diethy
  • the reaction temperature is usually, but not limited to, about 0°C to 200"C and preferably about 20°C to l50°C.
  • the reaction may be conducted for, usually, 30 minutes to 48 hours and preferably 2 hours to 24 hours.
  • compound of formula (XH) (wherein R 2' and R 3 are the same as defined above) can be prepared by the reaction of compound of formula (XI) (wherein R 2' and R 3 are the same as defined above) with the compound of formula (DI) or any salt form of (VIH).
  • the reaction can be advantageously carried out in the presence of a base including, for instance, ' sodium hydride, potassium hydride, sodium methoxide, sodium ethoxide, sodium hydroxide or potassium hydroxide, and the like.
  • the reaction can be carried out in a solvent including, for instance, ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene and xylene; dimethylformamide (DMF), dimethyl- acetamide(DMAC), l,3-dimethyl-3,4,5,6-tetrahydro-2(lH)-pyrimidinone (DMPU), l,3-dimethyl-2- imidazolidinone (DMI), N-methylpyrrolidinone (NMP), sulfoxides such as dimethylsulfoxide (DMSO), alcohols such as methanol, ethanol, 1-propanol, isopropanol and tert-butanol, water and others.
  • ethers such as diethyl ether, isopropyl ether, dioxane and t
  • the reaction temperature can be optionally set depending on the compounds to be reacted.
  • the reaction temperature is usually, but not limited to, about 20°C to 120°C.
  • the reaction may be conducted for, usually, 30 minutes to 48 hours and preferably 1 to 24 hours.
  • Step C-3 compound of formula (XDI) (wherein R 2 and R 3 are the same as defined above) can be prepared by the oxidation of sulfur atom of compound of formula (XH) (wherein R 2 and R 3 are the same as defined above).
  • the oxidation reaction can be performed using a reagent, such as hydrogen peroxide, sodium periodate, m-chloroperbenzoic acid (m-CPBA), potassium permanganate and others in the absence or presence of catalyst, such as catalytic ruthenium trichloride.
  • a reagent such as hydrogen peroxide, sodium periodate, m-chloroperbenzoic acid (m-CPBA), potassium permanganate and others in the absence or presence of catalyst, such as catalytic ruthenium trichloride.
  • the reaction can be carried out in solvent including, for instance, water, halogenated hydrocarbons such as, methylene chloride, carbon tetrachloride, chlorobenzene, dichloromethane, chloroform and 1,2-dichloroethane; ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene and xylene; nitriles such as acetonitrile; amides such as N, N-dimethylformamide (DMF), N, N-dimethylacetamide and N-methylpyrrolidone; and others.
  • solvent including, for instance, water, halogenated hydrocarbons such as, methylene chloride, carbon tetrachloride, chlorobenzene, dichloromethane, chloroform and 1,2-dichloroethane;
  • reaction temperature is usually, but not limited to about -10°C to 200°C, and preferably about 10°C to 50°C.
  • the reaction may be carried out for, usually, 30 minutes to 48 hours and preferably 1 hour to 20 hours.
  • compound of formula (F) (wherein R 1 , R 2 and R are the same as defined above) can be prepared by the reaction of compound of formula (XDI) (wherein R 2' and R 3 are the same as defined above) with compound of formula (VI) (wherein R 1 is the same as defined above).
  • the reaction may be carried out without solvent or in a solvent including, for instance, halogenated hydrocarbons such as dichloromethane, chloroform and 1,2-dichloroethane; alcohols such as methanol, ethanol, 1-propanol, isopropanol and tert-butanol; ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene and xylene; nitriles such as acetonitrile; amides such as N, N- dimethylformamide (DMF), N, N-dimethylacetamide (DMAC) and N-methylpyrrolidone (NMP); urea such as l,3-dimethyl-2-imidazolidinone (DMI); sulfoxides such as dimethylsulfoxide (DMSO); and others.
  • the reaction temperature can be optionally set depending on the compounds to be reacted.
  • the reaction temperature is usually, but not limited to, about 0°C to 200°C and preferably about 20°C to 150°C.
  • the reaction may be conducted for, usually, 10 minutes to 48 hours and preferably 30minutes to 24 hours.
  • the compound of formula (X) can be prepared by the use of known techniques or are commercially available.
  • Typical salts of the compound shown by the formula (I) include salts prepared by the reaction of the compound of the present invention with a mineral or organic acid, or an organic or inorganic base. Such salts are known as acid addition and base addition salts, respectively.
  • Acids to form acid addition salts include inorganic acids such as, without limitation, sulfuric acid, phosphoric acid, hydrochloric acid, hydrobromic acid, hydroiodic acid and the like, and organic acids, such as, without limitation, p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p- bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.
  • inorganic acids such as, without limitation, sulfuric acid, phosphoric acid, hydrochloric acid, hydrobromic acid, hydroiodic acid and the like
  • organic acids such as, without limitation, p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p- bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.
  • Base addition salts include those derived from inorganic bases, such as, without limitation, ammonium hydroxide, alkaline metal hydroxide, alkaline earth metal hydroxides, carbonates, bicarbonates, and the like, and organic bases, such as, without limitation, ethanolamine, triethyl- amine, fri(hydroxymethyl)aminomethane, and the like.
  • inorganic bases include, sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, calcium hydroxide, calcium carbonate, and the like.
  • the compound of the present invention or a salts thereof, depending on its substituents, may be modified to form lower alkylesters or known other esters; and or hydrates or other solvates. Those esters, hydrates, and solvates are included in the scope of the present invention.
  • the compound of the present invention may be administered in oral forms, such as, without limitation normal and enteric coated tablets, capsules, pills, powders, granules, elixirs, tinctures, solution, suspensions, syrups, solid and liquid aerosols and emulsions. They may also be administered in parenteral forms, such as, without limitation, intravenous, intraperitoneal, subcutaneous, intramuscular, and the like forms, well-known to those of ordinary skill in the pharmaceutical arts.
  • the compounds of the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using transdermal delivery systems well-known to those of ordinary skilled in the art.
  • the dosage regimen with the use of the compounds of the present invention is selected by one of ordinary skill in the arts, in view of a variety of factors, including, without limitation, age, weight, sex, and medical condition of the recipient, the severity of the condition to be treated, the route of administration, the level of metabolic and excretory function of the recipient, the dosage form employed, the particular compound and salt thereof employed.
  • the compounds of the present invention are preferably formulated prior to administration together with one or more pharmaceutically-acceptable excipients.
  • Excipients are inert substances such as, without limitation carriers, diluents, flavoring agents, sweeteners, lubricants, solubilizers, suspending agents, binders, tablet disintegrating agents and encapsulating material.
  • compositions of the present invention are pharmaceutical formulation comprising a compound of the invention and one or more pharmaceutically-acceptable excipients that are compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • Pharmaceutical formulations of the invention are prepared by combining a therapeutically effective amount of the compounds of the invention together with one or more pharmaceutically- acceptable excipients.
  • the active ingredient may be mixed with a diluent, or enclosed within a carrier, which may be in the form of a capsule, sachet, paper, or other container.
  • the carrier may serve as a diluent, which may be solid, semi- solid, or liquid material which acts as a vehicle, or can be in the form of tablets, pills, powders, lozenges, elixirs, suspensions, emulsions, solutions, syrups, aerosols, ointments, containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.
  • a diluent which may be solid, semi- solid, or liquid material which acts as a vehicle, or can be in the form of tablets, pills, powders, lozenges, elixirs, suspensions, emulsions, solutions, syrups, aerosols, ointments, containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.
  • the active ingredient may be combined with an oral, and non-toxic, pharmaceutically-acceptable carrier, such as, without limitation, lactose, starch, sucrose, glucose, sodium carbonate, mannitol, sorbitol, calcium carbonate, calcium phosphate, calcium sulfate, methyl cellulose, and the like; together with, optionally, disintegrating agents, such as, without limitation, maize, starch, methyl cellulose, agar bentonite, xanthan gum, alginic acid, and the like; and optionally, binding agents, for example, without limitation, gelatin, natural sugars, beta- lactose, corn sweeteners, natural and synthetic gums, acacia, tragacanth, sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like; and, optionally, lubricating agents, for example, without limitation, magnesium stearate, sodium stearate, stearic acid, sodium oleate, sodium benzoate,
  • the carrier may be a finely divided solid which is in admixture with the finely divided active ingredient.
  • the active ingredient may be mixed with a carrier having binding properties in suitable proportions and compacted in the shape and size desired to produce tablets.
  • the powders and tablets preferably contain from about 1 to about 99 weight percent of the active ingredient which is the novel composition of the present invention.
  • Suitable solid carriers are magnesium carboxymethyl cellulose, low melting waxes, and cocoa butter.
  • Sterile liquid formulations include suspensions, emulsions, syrups and elixirs.
  • the active ingredient can be dissolved or suspended in a pharmaceutically acceptable carrier, such as sterile water, sterile organic solvent, or a mixture of both sterile water and a sterile organic solvent.
  • the active ingredient can also be dissolved in a suitable organic solvent, for example, aqueous propylene glycol.
  • a suitable organic solvent for example, aqueous propylene glycol.
  • Other compositions can be made by dispersing the finely divided active ingredient in aqueous starch or sodium carboxymethyl cellulose solution or in a suitable oil.
  • the formulation may be in unit dosage form, which is a physically discrete unit containing a unit dose, suitable for administration in human or other mammals.
  • a unit dosage ' form can be a capsule or tablets, or a number of capsules or tablets.
  • a "unit dose" is a predetermined quantity of the active compound of the present invention, calculated to produce the desired therapeutic effect, in association with one or more excipients.
  • the quantity of active ingredient in a unit dose may be varied or adjusted from about 0.1 to about 1000 milligrams or more according to the particular treatment involved.
  • Typical oral dosages of the present invention when used for the indicated effects, will range from about O.Olmg/kg/day to about lOOmg/kg/day, preferably from 0.1 mg/kg/day to 30 mg/kg/day, and most preferably from about 0.5 mg/kg/day to about 10 mg/kg/day. .
  • parenteral administration it has generally proven advantageous to administer quantities of about 0.001 to 100 mg/kg/day, preferably from 0.01 mg/kg/day to lmg/kg/day.
  • the compounds of the present invention may be administered in a single daily dose, or the total daily dose may be administered in divided doses, two, three, or more times per day. Where delivery is via transdermal forms, of course, administration is continuous.
  • a fusion construct consisting of the n-terminal part of H 4 and the C-terminal part of the Gr protein Got ! 6 was transfected into CHO cells containing the aequorin-controlled luciferase gene (CHOAQLuci cells). Recombinant clones showing aequorin luminescence after the addition of 1 ⁇ M histamine were isolated. Starting with three independent primary cell clones three sets of tertiary clones were generated by two successive rounds of limiting dilution.
  • CHO-H4 cells were seeded at 2 x 10 4 cells per well in Biocoat poly-D-Lysine 96 well black/clear plates (BECTON DICKINSON, Franklin Lakes, US) in D-MEM/F12 medium supplemented with 10% FCS and 400 ⁇ g/ml Geneticin (Invitrogen GD3CO, Carlsbad, US) and 2 mM butylrate for O/N.
  • the medium was removed and cells were loaded with 1 ⁇ M Fluo-3 (Molecular Probes, Eugene, USA) in loading solution (0.1% BSA, 20mM HEPES Hank's Buffer, ImM probinecid) for 1 hour.
  • the loading buffer was removed and exchanged for fresh loading buffer.
  • Cells were pretreated with various concentrations of test compounds and subjected to calcium mobilization measurement induced by 100 nM histamine by using FDSS6000.
  • Membrane fraction was prepared from CHO-H 4 stable cells treated with 5 mM butyrate for O/N. 20 nM 3 H-histamine binding to membrane was performed in 50 mM Tris (pH 7.5 ), 5 mM EDTA for 1 hour in the presence of test compounds. Non-specific binding was determined in the presence of 20 ⁇ M histamine. B/F separation was performed by filtration using MAFB NOB plate . (Millipore, Tokyo, JAPAN ) with 3 times wash by 50 mM Tris ( pH7.5 ), 0.5 mM EDTA.
  • Bone marrow-derived mast cells were generated from the femural bone marrow of 6-8 week old male mice and maintained in RPMI1640 medium (Nacalai Tesque, Kyoto Japan) supplemented with 10% fetal bovine serum (FBS; JRH Bioscience, Lenex, KS, US), 100 units/ml penicilline-streptpmycine (GIBCO BRL, Rockville, MD, US) and 10 ng/ml recombinant murine IL-3 (Pepro Tech EC Ltd., London, UK) at a density of lxl 0 6 cells/ml. Prior to experimentation, BMMC were harvested, washed twice in PBS and further used as indicated. Purity of mast cells was >95% as asessed by Toluidine blue staining or FACS analysis of cell surface expression of c- kit and Fc ⁇ RI.
  • Transwell plates (Costar, NY, USA) with a pore size of 8 ⁇ m were coated with 100 ⁇ l of 100 ng / ml human fibronectin for 2hours at room temperature. After removal of fibronectin 600 ⁇ l of RPMI containing 10% FCS in the presence of histamine were added to the bottom chamber. Subsequently, bone marrow-derived mast cells (2 x 10 5 / well in 100 ⁇ l ) pre-treated with antagonists or test compounds were added to the top chambers. The plates were incubated for 2 hours at 37°C degrees. Transwells were removed and the number of cells in the bottom chamber was counted by flow cytometer. [Zymosan-induced pleurisy in mice] (Assay 4)
  • mice (Balb/c, female, 7-8 weeks old, SPF, Charles River Inc.) received a single intrapleural injection with 0.2 ml zymosan (100 ⁇ g/mouse) under anesthetization with ether.
  • Test compounds thi ⁇ peramide, dexamethasone, and vehicle (10 % cremophor in PBS)
  • mice were sacrificed and pleural fluid was collected by washing the pleural cavity twice with 2 ml PBS.
  • the cell suspension was diluted to one tenth in Turk's stain solution (Nacalai Tesque).
  • the number of total cells in the sample was counted under the microscope using a hemocytometer. Cytospin specimens were stained with May-Gruenwald's (Merck, Darmstadt, Germany) and Giemsa's solution (Merck) for leukocyte typing. The distribution of each cell population (neutrophils, eosinophils, macrophages, lymphocytes and others) was counted under microscopy by counting more than 200 cells.
  • Assay results in Assay 1 are shown in Examples and tables of the Examples below. For practical reasons, the compounds are grouped in four classes of activity as follows: A ⁇ IC 50 20nM ⁇ B ⁇ IC 50 lOOnM ⁇ C ⁇ IC 50 500nM ⁇ D
  • the compounds of the present invention also show excellent selectivity, and potent activity in Assays 2 - 4 described above.
  • Examplel-1 and 1-2 In the similar manners as described in Examplel-1 and 1-2 above, the compounds in Example 1-3 to 1-29 as shown in Table 1 were synthesized.

Abstract

L'invention concerne de nouveaux dérivés de 2-aminopyrimidine, des procédés de préparation de ces dérivés et des préparations pharmaceutiques contenant ces dérivés. Les dérivés de 2-aminopyrimidine selon l'invention présentent une meilleure puissance pour l'antagonisme du récepteur de l'histamine H4 et peuvent être utilisés pour la prévention et le traitement de maladies associées à l'activité du récepteur de l'histamine H4. D'une manière plus spécifique, les dérivés de 2-aminopyrimidine selon l'invention sont utiles pour le traitement et la prévention des maladies suivantes : asthme, rhinite, maladies allergiques, bronchopneumopathie chronique obstructive, athérosclérose, polyarthrite rhumatoïde, maladies ou troubles thromboemboliques et maladies ou troubles urologiques.
PCT/EP2004/013322 2003-12-05 2004-11-24 Derives de 2-aminopyrimidine WO2005054239A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03028102.6 2003-12-05
EP03028102 2003-12-05

Publications (1)

Publication Number Publication Date
WO2005054239A1 true WO2005054239A1 (fr) 2005-06-16

Family

ID=34639279

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/013322 WO2005054239A1 (fr) 2003-12-05 2004-11-24 Derives de 2-aminopyrimidine

Country Status (1)

Country Link
WO (1) WO2005054239A1 (fr)

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007090854A1 (fr) * 2006-02-10 2007-08-16 Cellzome (Uk) Ltd. Composés d'amino pyrimidine d'azétidine destinés à traiter des troubles inflammatoires
WO2007072163A3 (fr) * 2005-12-20 2007-10-04 Pfizer Ltd Derives de pyrimidine
WO2007117401A2 (fr) 2006-04-07 2007-10-18 Janssen Pharmaceutica N.V. Indoles et benzoimidazoles modulateurs du récepteur de l'histamine h4
EP1860109A1 (fr) * 2006-05-24 2007-11-28 Cellzome (UK) Ltd. Composés d'amino pyrimidine substitués avec une azetidine pour traiter les maladies inflammatoires
WO2008031556A2 (fr) * 2006-09-12 2008-03-20 Ucb Pharma, S.A. Nouveaux dérivés de la 2-amino-pyrimidine, procédés pour les préparer, compositions pharmaceutiques les contenant
WO2008060766A2 (fr) * 2006-10-02 2008-05-22 Abbott Laboratories Procédé pour le traitement de la douleur
WO2008100565A1 (fr) * 2007-02-14 2008-08-21 Janssen Pharmaceutica N.V. 2-aminopyrimidines en tant que modulateurs du récepteur h4 de l'histamine
WO2008122378A1 (fr) * 2007-04-04 2008-10-16 Ucb Pharma, S.A. Nouveaux derives de pyridine, procedes de preparation et compositions pharmaceutiques associes
WO2009047255A1 (fr) * 2007-10-09 2009-04-16 Ucb Pharma, S.A. Composés hétérobicycliques utiles comme antagonistes du récepteur h4 de l'histamine
WO2009068512A1 (fr) * 2007-11-30 2009-06-04 Palau Pharma, S. A. Dérivés de 2-aminopyrimidine en tant qu'antagonistes d'histamine h4
WO2009077608A1 (fr) * 2007-12-19 2009-06-25 Palau Pharma, S. A. Dérivés de 2-aminopyrimidine comme antagonistes des récepteurs h4 de l'histamine
WO2009080721A2 (fr) * 2007-12-21 2009-07-02 Palau Pharma, S. A. Dérivés de 4-aminopyridine
JP2009527578A (ja) * 2006-02-24 2009-07-30 アボット・ラボラトリーズ オクタヒドロ−ピロロ［３，４−ｂ］ピロール誘導体およびそれらのヒスタミン−３受容体リガンドとしての使用
WO2009114575A1 (fr) * 2008-03-11 2009-09-17 Abbott Laboratories Dérivés de spiropyrimidine tricyclique en tant que ligand d'histamine h4
WO2009115496A1 (fr) * 2008-03-17 2009-09-24 Palau Pharma, S. A. Dérivés de la furo[3,2-d]pyrimidine en tant qu'antagonistes des récepteurs de h4
WO2009123967A1 (fr) * 2008-04-03 2009-10-08 Abbott Laboratories Dérivés de 5,6,7,8-tétrahydroquinazolin-2-amine et composés associés en tant que modulateurs du récepteur d’histamine h4 pour le traitement de l’asthme
EP2201982A1 (fr) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonistes du récepteur H4 de l'histamine pour le traitement de troubles vestibulaires
WO2010084050A2 (fr) 2009-01-13 2010-07-29 Novartis Ag Dérivés de quinazolinone utiles comme antagonistes vanilloïdes
WO2010100215A1 (fr) 2009-03-06 2010-09-10 F.I.S. Fabbrica Italiana Sintetici S.P.A. Synthèse de la (4as, 7as)-octahydro-1h-pyrrolo[3,4-b]pyridine
WO2010108059A1 (fr) * 2009-03-20 2010-09-23 Incyte Corporation Dérivés substitués de pyrimidine en tant qu'antagonistes du récepteur histaminique h4
EP2305652A2 (fr) 2005-12-08 2011-04-06 Novartis AG Dérivés de quinazolinone trisubstituée en tant qu'agonistes de vanilloïde
EP2315521A1 (fr) * 2008-06-12 2011-05-04 Janssen Pharmaceutica NV Modulateurs de diamino-pyridine, pyrimidine et pyridazine du récepteur de l'histamine h 4
WO2011092290A1 (fr) 2010-02-01 2011-08-04 Novartis Ag Dérivés de pyrazolo[5,1-b] utilisés en tant qu'antagonistes du récepteur de crf-1
WO2011092293A2 (fr) 2010-02-01 2011-08-04 Novartis Ag Dérivés de cyclohexylamide utilisés en tant qu'antagonistes du récepteur du crf
WO2011095450A1 (fr) 2010-02-02 2011-08-11 Novartis Ag Dérivés de cyclohexylamide à titre d'antagonistes du récepteur crf
US8193178B2 (en) 2007-09-14 2012-06-05 Janssen Pharmaceutica Nv Thieno- and furo-pyrimidine modulators of the histamine H4 receptor
WO2012164473A1 (fr) 2011-05-27 2012-12-06 Novartis Ag Dérivés de pipéridine 3-spirocyclique comme agonistes du récepteur de la ghréline
JP2013505949A (ja) * 2009-09-25 2013-02-21 エヌサーティー・ファーマシューティカルズ・インコーポレーテッド Ｓ−ニトロソグルタチオンレダクターゼ阻害薬としての新規ジヒドロピリミジン−２（１ｈ）−オン化合物
US8436008B2 (en) 2008-12-22 2013-05-07 Incyte Corporation Substituted heterocyclic compounds
WO2013164790A1 (fr) 2012-05-03 2013-11-07 Novartis Ag Sel de l-malate de dérivés de 2,7-diaza-spiro[4.5]déc-7-yle et ses formes cristallines à titre d'agonistes des récepteurs de ghreline
WO2013182711A1 (fr) 2012-06-08 2013-12-12 Sensorion Inhibiteurs des récepteurs h4 pour le traitement des acouphènes
US8901146B2 (en) 2009-12-23 2014-12-02 Medicis Pharmaceutical Corporation Aminoalkylpyrimidine derivatives as histamine H4 receptor antagonists
EP3195867A1 (fr) * 2011-02-28 2017-07-26 Ustav Organicke Chemie A Biochemie Akademie Ved Cr, v.v.i. Composés de pyrimidine inhibant la formation d'oxyde nitrique et prostaglandine e2, leur procédé de production et leur utilisation
WO2017131171A1 (fr) * 2016-01-29 2017-08-03 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Nouveau composé et sel pharmaceutiquement acceptable de celui-ci
WO2020079457A1 (fr) * 2018-10-19 2020-04-23 Heptares Therapeutics Limited Dérivés de pyrazole en tant que composés antagonistes de h4
WO2021214469A1 (fr) * 2020-04-22 2021-10-28 Heptares Therapeutics Limited Composés antagonistes du h4

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047921A1 (fr) * 1999-12-28 2001-07-05 Pharmacopeia, Inc. Composes de pyrimidine et de triazine presentant une activite inhibant la kinase
WO2001062233A2 (fr) * 2000-02-25 2001-08-30 F. Hoffmann La Roche Ag Modulateurs de recepteurs de l'adenosine
WO2002096867A2 (fr) * 2001-05-30 2002-12-05 Lg Biomedical Institute Inhibiteurs de la proteine kinase destines au traitement d'une maladie

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047921A1 (fr) * 1999-12-28 2001-07-05 Pharmacopeia, Inc. Composes de pyrimidine et de triazine presentant une activite inhibant la kinase
WO2001062233A2 (fr) * 2000-02-25 2001-08-30 F. Hoffmann La Roche Ag Modulateurs de recepteurs de l'adenosine
WO2002096867A2 (fr) * 2001-05-30 2002-12-05 Lg Biomedical Institute Inhibiteurs de la proteine kinase destines au traitement d'une maladie

Cited By (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2305652A2 (fr) 2005-12-08 2011-04-06 Novartis AG Dérivés de quinazolinone trisubstituée en tant qu'agonistes de vanilloïde
NO341075B1 (no) * 2005-12-20 2017-08-21 Ziarco Pharma Ltd Pyrimidinderivater, fremgangsmåter for fremstilling derav, farmasøytiske sammensetninger inneholdende slike derivater og anvendelse av slike derivater
WO2007072163A3 (fr) * 2005-12-20 2007-10-04 Pfizer Ltd Derives de pyrimidine
NL2000323C2 (nl) * 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
US7943628B2 (en) 2005-12-20 2011-05-17 Pfizer Limited Pyrimidine derivatives
KR101152719B1 (ko) * 2005-12-20 2012-06-18 화이자 리미티드 피리미딘 유도체
AU2006327876B2 (en) * 2005-12-20 2010-12-16 Ziarco Inc. Pyrimidine derivatives
JP2009520019A (ja) * 2005-12-20 2009-05-21 ファイザー・リミテッド ピリミジン誘導体
WO2007090854A1 (fr) * 2006-02-10 2007-08-16 Cellzome (Uk) Ltd. Composés d'amino pyrimidine d'azétidine destinés à traiter des troubles inflammatoires
JP2009527578A (ja) * 2006-02-24 2009-07-30 アボット・ラボラトリーズ オクタヒドロ−ピロロ［３，４−ｂ］ピロール誘導体およびそれらのヒスタミン−３受容体リガンドとしての使用
US7544698B2 (en) 2006-04-07 2009-06-09 Janssen Pharmaceutica, N.V. Indoles and benzoimidazoles as modulators of the histamine H4 receptor
WO2007117401A2 (fr) 2006-04-07 2007-10-18 Janssen Pharmaceutica N.V. Indoles et benzoimidazoles modulateurs du récepteur de l'histamine h4
JP2009533343A (ja) * 2006-04-07 2009-09-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンｈ４受容体のモジュレーターとしてのインドールおよびベンゾイミダゾール
EP1860109A1 (fr) * 2006-05-24 2007-11-28 Cellzome (UK) Ltd. Composés d'amino pyrimidine substitués avec une azetidine pour traiter les maladies inflammatoires
WO2008031556A2 (fr) * 2006-09-12 2008-03-20 Ucb Pharma, S.A. Nouveaux dérivés de la 2-amino-pyrimidine, procédés pour les préparer, compositions pharmaceutiques les contenant
WO2008031556A3 (fr) * 2006-09-12 2008-06-12 Ucb Pharma Sa Nouveaux dérivés de la 2-amino-pyrimidine, procédés pour les préparer, compositions pharmaceutiques les contenant
WO2008060766A3 (fr) * 2006-10-02 2009-02-19 Abbott Lab Procédé pour le traitement de la douleur
US7985745B2 (en) 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
WO2008060766A2 (fr) * 2006-10-02 2008-05-22 Abbott Laboratories Procédé pour le traitement de la douleur
US8415366B2 (en) 2007-02-14 2013-04-09 Janssen Pharmaceutica Nv 2-aminopyrimidine modulators of the histamine H4 receptor
EP2599386A1 (fr) 2007-02-14 2013-06-05 Janssen Pharmaceutica N.V. Modulateurs 2-aminopyrimidine du récepteur h4 d'histamine
AU2008216727B2 (en) * 2007-02-14 2013-07-11 Janssen Pharmaceutica N.V. 2-aminopyrimidine modulators of the histamine H4 receptor
US8686142B2 (en) 2007-02-14 2014-04-01 Janssen Pharmaceutica Nv 2-aminopyrimidine modulators of the histamine H4 receptor
EA016133B1 (ru) * 2007-02-14 2012-02-28 Янссен Фармацевтика Н.В. 2-аминопиримидиновые модуляторы рецептора нгистамина, способ их получения, фармацевтические композиции и способ их применения для модуляции рецептора hгистамина
WO2008100565A1 (fr) * 2007-02-14 2008-08-21 Janssen Pharmaceutica N.V. 2-aminopyrimidines en tant que modulateurs du récepteur h4 de l'histamine
US8716475B2 (en) 2007-02-14 2014-05-06 Janssen Pharmaceutica Nv 2-aminopyrimidine modulators of the histamine H4 receptor
US7923451B2 (en) 2007-02-14 2011-04-12 Janssen Pharmaceutica Nv 2-aminopyrimidine modulators of the histamine H4 receptor
WO2008122378A1 (fr) * 2007-04-04 2008-10-16 Ucb Pharma, S.A. Nouveaux derives de pyridine, procedes de preparation et compositions pharmaceutiques associes
US8193178B2 (en) 2007-09-14 2012-06-05 Janssen Pharmaceutica Nv Thieno- and furo-pyrimidine modulators of the histamine H4 receptor
US8440654B2 (en) 2007-09-14 2013-05-14 Janssen Pharmaceutica Nv Thieno- and furo-pyrimidine modulators of the histamine H4 receptor
US8937075B2 (en) 2007-09-14 2015-01-20 Janssen Pharmaceutica, Nv Thieno- and furo-pyrimidine modulators of the histamine H4 receptor
US8927555B2 (en) 2007-09-14 2015-01-06 Janssen Pharmaceutica, Nv Thieno- and furo-pyrimidine modulators of the histamine H4 receptor
US8445482B2 (en) 2007-09-14 2013-05-21 Janssen Pharmaceutica Nv Thieno- and furo-pyrimidine modulators of the histamine H4 receptor
WO2009047255A1 (fr) * 2007-10-09 2009-04-16 Ucb Pharma, S.A. Composés hétérobicycliques utiles comme antagonistes du récepteur h4 de l'histamine
WO2009068512A1 (fr) * 2007-11-30 2009-06-04 Palau Pharma, S. A. Dérivés de 2-aminopyrimidine en tant qu'antagonistes d'histamine h4
WO2009077608A1 (fr) * 2007-12-19 2009-06-25 Palau Pharma, S. A. Dérivés de 2-aminopyrimidine comme antagonistes des récepteurs h4 de l'histamine
KR101639819B1 (ko) * 2007-12-21 2016-07-14 팔라우 파르마 에스에이 히스타민 ｈ４ 수용체 길항제로서 ４-아미노피리미딘 유도체
CN101903385B (zh) * 2007-12-21 2013-11-06 帕劳制药股份有限公司 作为组胺h4受体拮抗剂的4-氨基嘧啶衍生物
JP2011506566A (ja) * 2007-12-21 2011-03-03 パラウ・フアルマ・ソシエダツド・アノニマ ヒスタミンｈ４受容体アンタゴニストとしての４−アミノピリミジン誘導体
KR20100096184A (ko) * 2007-12-21 2010-09-01 팔라우 파르마 에스에이 히스타민 ｈ４ 수용체 길항제로서 ４-아미노피리미딘 유도체
RU2489430C2 (ru) * 2007-12-21 2013-08-10 Палау Фарма, С.А. Производные 4-аминопиримидина
WO2009080721A2 (fr) * 2007-12-21 2009-07-02 Palau Pharma, S. A. Dérivés de 4-aminopyridine
WO2009080721A3 (fr) * 2007-12-21 2009-09-11 Palau Pharma, S. A. Dérivés de 4-aminopyridine
US8431580B2 (en) 2007-12-21 2013-04-30 Palau Pharma, S.A. 4-aminopyrimidine derivatives as histamine H4 receptor antagonists
AU2008341678B2 (en) * 2007-12-21 2013-03-21 Palau Pharma, S. A. 4 -aminopyrimidine derivatives as histamine H4 receptor antagonists
US8278313B2 (en) 2008-03-11 2012-10-02 Abbott Laboratories Macrocyclic spiro pyrimidine derivatives
WO2009114575A1 (fr) * 2008-03-11 2009-09-17 Abbott Laboratories Dérivés de spiropyrimidine tricyclique en tant que ligand d'histamine h4
WO2009115496A1 (fr) * 2008-03-17 2009-09-24 Palau Pharma, S. A. Dérivés de la furo[3,2-d]pyrimidine en tant qu'antagonistes des récepteurs de h4
WO2009123967A1 (fr) * 2008-04-03 2009-10-08 Abbott Laboratories Dérivés de 5,6,7,8-tétrahydroquinazolin-2-amine et composés associés en tant que modulateurs du récepteur d’histamine h4 pour le traitement de l’asthme
US8436005B2 (en) 2008-04-03 2013-05-07 Abbott Laboratories Macrocyclic pyrimidine derivatives
EP2315521A1 (fr) * 2008-06-12 2011-05-04 Janssen Pharmaceutica NV Modulateurs de diamino-pyridine, pyrimidine et pyridazine du récepteur de l'histamine h 4
JP2011524363A (ja) * 2008-06-12 2011-09-01 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンｈ４受容体のジアミノピリジン、ピリミジン、及びピリダジンモジュレーター
US8841287B2 (en) 2008-06-12 2014-09-23 Janssen Pharmaceutica N.V. Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor
CN102118969A (zh) * 2008-06-12 2011-07-06 詹森药业有限公司 组胺h4受体的二氨基吡啶、二氨基嘧啶和二氨基哒嗪调节剂
EP2315521A4 (fr) * 2008-06-12 2012-04-25 Janssen Pharmaceutica Nv Modulateurs de diamino-pyridine, pyrimidine et pyridazine du récepteur de l'histamine h 4
US9732087B2 (en) 2008-06-12 2017-08-15 Janssen Pharmaceutica N.V. Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine H4 receptor
US8436008B2 (en) 2008-12-22 2013-05-07 Incyte Corporation Substituted heterocyclic compounds
US9526725B2 (en) 2008-12-24 2016-12-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Selective histamine H4 receptor antagonists for the treatment of vestibular disorders
EP2201982A1 (fr) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonistes du récepteur H4 de l'histamine pour le traitement de troubles vestibulaires
US10195195B2 (en) 2008-12-24 2019-02-05 Inserm (Institut National De La Sante Et De La Recherche Medicale) Selective histamine H4 receptor antagonists for the treatment of vestibular disorders
WO2010072829A1 (fr) 2008-12-24 2010-07-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonistes sélectifs du récepteur h4 de l'histamine dans le traitement de troubles vestibulaires
WO2010084050A2 (fr) 2009-01-13 2010-07-29 Novartis Ag Dérivés de quinazolinone utiles comme antagonistes vanilloïdes
WO2010100215A1 (fr) 2009-03-06 2010-09-10 F.I.S. Fabbrica Italiana Sintetici S.P.A. Synthèse de la (4as, 7as)-octahydro-1h-pyrrolo[3,4-b]pyridine
US8481732B2 (en) 2009-03-20 2013-07-09 Incyte Corporation Substituted heterocyclic compounds
WO2010108059A1 (fr) * 2009-03-20 2010-09-23 Incyte Corporation Dérivés substitués de pyrimidine en tant qu'antagonistes du récepteur histaminique h4
JP2013505949A (ja) * 2009-09-25 2013-02-21 エヌサーティー・ファーマシューティカルズ・インコーポレーテッド Ｓ−ニトロソグルタチオンレダクターゼ阻害薬としての新規ジヒドロピリミジン−２（１ｈ）−オン化合物
US8901146B2 (en) 2009-12-23 2014-12-02 Medicis Pharmaceutical Corporation Aminoalkylpyrimidine derivatives as histamine H4 receptor antagonists
WO2011092290A1 (fr) 2010-02-01 2011-08-04 Novartis Ag Dérivés de pyrazolo[5,1-b] utilisés en tant qu'antagonistes du récepteur de crf-1
WO2011092293A2 (fr) 2010-02-01 2011-08-04 Novartis Ag Dérivés de cyclohexylamide utilisés en tant qu'antagonistes du récepteur du crf
WO2011095450A1 (fr) 2010-02-02 2011-08-11 Novartis Ag Dérivés de cyclohexylamide à titre d'antagonistes du récepteur crf
EP3195867A1 (fr) * 2011-02-28 2017-07-26 Ustav Organicke Chemie A Biochemie Akademie Ved Cr, v.v.i. Composés de pyrimidine inhibant la formation d'oxyde nitrique et prostaglandine e2, leur procédé de production et leur utilisation
WO2012164473A1 (fr) 2011-05-27 2012-12-06 Novartis Ag Dérivés de pipéridine 3-spirocyclique comme agonistes du récepteur de la ghréline
WO2013164790A1 (fr) 2012-05-03 2013-11-07 Novartis Ag Sel de l-malate de dérivés de 2,7-diaza-spiro[4.5]déc-7-yle et ses formes cristallines à titre d'agonistes des récepteurs de ghreline
US9688989B2 (en) 2012-06-08 2017-06-27 Sensorion H4 receptor inhibitors for treating tinnitus
WO2013182711A1 (fr) 2012-06-08 2013-12-12 Sensorion Inhibiteurs des récepteurs h4 pour le traitement des acouphènes
EP3378476A1 (fr) 2012-06-08 2018-09-26 Sensorion Inhibiteurs du récepteur h4 destinés au traitement des acouphènes
CN108602780A (zh) * 2016-01-29 2018-09-28 明治制果药业株式会社 新的化合物及其药理学上可接受的盐
WO2017131171A1 (fr) * 2016-01-29 2017-08-03 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Nouveau composé et sel pharmaceutiquement acceptable de celui-ci
WO2020079457A1 (fr) * 2018-10-19 2020-04-23 Heptares Therapeutics Limited Dérivés de pyrazole en tant que composés antagonistes de h4
CN113272297A (zh) * 2018-10-19 2021-08-17 赫普泰雅治疗有限公司 作为h4拮抗剂化合物的吡唑衍生物
US20210300906A1 (en) * 2018-10-19 2021-09-30 Heptares Therapeutics Limited Pyrazole derivatives as h4 antagonist compounds
CN113272297B (zh) * 2018-10-19 2024-03-19 赫普泰雅治疗有限公司 作为h4拮抗剂化合物的吡唑衍生物
WO2021214469A1 (fr) * 2020-04-22 2021-10-28 Heptares Therapeutics Limited Composés antagonistes du h4
CN115916770A (zh) * 2020-04-22 2023-04-04 赫普泰雅治疗有限公司 H4拮抗剂化合物

Similar Documents

Publication Publication Date Title
WO2005054239A1 (fr) Derives de 2-aminopyrimidine
EP1505064A1 (fr) Dérivés de 2-aminopyrimidine
KR101148261B1 (ko) 종양성 질환, 염증성 및 면역계 장애의 치료에 유용한2,4-디(페닐아미노)피리미딘
JP4607879B2 (ja) 新生物疾患、炎症および免疫障害の処置に有用な２，４−ピリミジンジアミン
EP1471057B1 (fr) Derivés de l'acid pyrimidinylacétique pour le traitment des maladies associées au CRTH2
KR101238591B1 (ko) 키나아제 억제제로서의 피리미딘 우레아 유도체
JP4996257B2 (ja) イミダゾ［１，２−ｃ］ピリミジニル酢酸誘導体
AU2002227984A1 (en) Novel sulfamides and their use as endothelin receptor antagonists
CA2709650C (fr) Derives de 4-aminopyridine comme antagonistes du recepteur histamine h4
AU2005276582A1 (en) Pyrimidine derivatives
US6596719B1 (en) 6 alkoxy-4-pyrimidinyl bis-sulfonamides
WO2005019182A1 (fr) Derives de pyrazolylmethylbenzamide utilises comme antagonistes du recepteur p2xt
AU2002212171B2 (en) Arylalkane-sulfonamides having endothelin-antagonist activity
WO2001081338A1 (fr) Sulfonylaminopyrimidines substituees
AU2002212171A1 (en) Arylalkane-sulfonamides having endothelin-antagonist activity
US6720322B2 (en) Butyne diol derivatives
EP1322624A1 (fr) Arylalcane-sulfonamides
CA2237774A1 (fr) Dihydropirimidines et leurs emplois

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase